Learn with Anil · APPSC Group-I PYQsPractise online →Subscribe ₹149
LVM3 lifting off with Chandrayaan-3 from Sriharikota, Andhra Pradesh

Photo: LVM3 launch, Sriharikota, ISRO, GODL-India

APPSC Group-I Mains 2025 · Paper V

2025 Paper V · Q12(b): model answer

Science, Technology & Environmental Issues · Biotechnology and health. Held in May 2025 (Notification 12/2023).

Q12(b)10 marks2025 · Paper V

Trace the evolution of India's National Biotechnology Development Strategy (NBDS) and discuss its key objectives. Critically evaluate its impact on the growth of the biotechnology sector in India.

Syllabus: Biotechnology and health · Biotechnology

Model answer · free

NBDSDBT and BIRACBioeconomyBioE3 Policy

The National Biotechnology Development Strategy (NBDS) is the Department of Biotechnology's roadmap for turning India's biological science base into products, jobs and a bioeconomy. Since DBT was set up in 1986, three strategies (2007, 2015–2020 and 2021–2025) shifted the focus from building research capacity to manufacturing and commercialisation, a path now carried forward by the BioE3 Policy (2024).

1. Evolution

  1. 1986 Department of Biotechnology set up
  2. 2007 First NBDS: people, infrastructure, partnerships
  3. 2012 BIRAC set up as DBT's industry interface
  4. 2015 NBDS 2015–2020: "Mission US$100 billion"
  5. 2021 NBDS 2021–2025, the third strategy
  6. 2024 BioE3 Policy and Bio-RIDE scheme
From DBT to BioE3
  • NBDS 2007: after two decades of public investment, it aimed to build human resources, research infrastructure and public–private partnership, and proposed a single biotechnology regulator (later the lapsed BRAI Bill, 2013).
  • NBDS 2015–2020: aimed to make India a "world class bio-manufacturing hub" and a US$100 billion industry by 2025, through four missions (healthcare, food and nutrition, clean energy, education) and a translation network of 5 new clusters, 40 incubators, 150 technology transfer offices and 20 bio-connect centres.
  • NBDS 2021–2025: continued the push for start-ups, bio-manufacturing and translation.
  • BioE3 (24 August 2024): biomanufacturing hubs, biofoundries and Bio-AI hubs in six areas; Bio-RIDE (₹9,197 crore) merged DBT's schemes.

2. Key objectives

  • Human capital: skilled scientists and entrepreneurs; a Life Sciences and Biotechnology Education Council.
  • Research base: genomics, vaccines, stem cells, agri-biotech, marine biotechnology, bioprospecting.
  • Translation: incubators, technology transfer offices and BIRAC grants and equity for start-ups.
  • Inclusive development: affordable healthcare, food and nutrition, clean energy and environment.
  • Enablers: transparent regulation and global partnerships.

3. Impact: a critical evaluation

2014102024165.72025195.32030 target300
India's bioeconomy (US$ billion, India BioEconomy Report 2026)
  • Growth: the bioeconomy grew nearly twentyfold to US$195.3 billion in 2025 (about 4.8% of GDP), well past the 2015 strategy's US$100 billion goal, with about 11,800 start-ups.
  • Health products: India makes nearly 60% of the world's vaccines; Covaxin, ZyCoV-D (the first human DNA vaccine), the HPV vaccine CERVAVAC (DBT-BIRAC), NexCAR19 CAR-T therapy (2023) and BIRSA 101 for sickle cell disease (2025).
  • Agriculture and genomics: genome-edited rice (2025) and the 10,000-genome Genome India Project.
  • Shortfalls: national R&D spending is only 0.84% of GDP (2023-24); much output is biosimilars, generics and services rather than new discoveries; regulatory delays have stalled agri-biotech beyond Bt cotton; reagents and equipment are largely imported; start-ups cluster in a few States.

AP angle: Andhra Pradesh's bioeconomy was US$13.74 billion in 2025, fifth among States; the AP MedTech Zone, Visakhapatnam (2016), and AP-bred rice parents of the genome-edited varieties show its potential.

The NBDS turned biotechnology from a laboratory pursuit into a US$195 billion sector; reaching US$300 billion by 2030 needs higher R&D spending, a modern regulator and bio-manufacturing spread beyond a few clusters.

The other choice in Q12

Answer either one in the exam.

  1. Q12(a)Explain the regulatory framework governing genetically modified organisms in India and assess its adequacy in addressing modern challenges.

    10 marks · Biotechnology and health · Biotechnology

Write better answers: the Answer Writing Tool Kit

Every model answer on these pages is free to read. The Tool Kit adds four PDF books for Mains Papers I–IV: every previous question sorted by syllabus, with practice questions. It is in the ₹149 All-in-One Pass, with every previous paper of every exam on the site, practice quizzes, timed tests, mock test series and study books.

₹149 · valid for 12 months from the day you pay, on every exam · pay by UPI, card or net banking

Get it for ₹149